search
Back to results

Evaluation of a Hearing Device for Transmitting Sound to the Inner Ear

Primary Purpose

Conductive Hearing Loss, Mixed Hearing Loss

Status
Active
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Sentio 1
Sponsored by
Oticon Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Conductive Hearing Loss

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Signed Informed Consent Form Adult subjects (18 years or older) Subjects implanted with an I1 implant Fluent in Swedish Exclusion Criteria: Subjects who do not have the ability or are un-willing to follow investigational procedures/requirements, e.g., to complete questionnaires, according to investigator's discretion. Subject deemed unsuitable for any medical or other reason as judged by PI or medical responsible.

Sites / Locations

  • Habilitation & Health, Hearing organization

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Sentio 1 sound processor

Arm Description

The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.

Outcomes

Primary Outcome Measures

To assess the improvement of hearing with the Sentio1 (PTA4)
Functional gain with Sentio 1, i.e., the difference in dB between unaided and aided sound field thresholds, calculated on average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).

Secondary Outcome Measures

To assess the improvement of hearing with the Sentio1
Functional gain with Sentio 1, i.e., the difference in dB between unaided and aided sound field thresholds, for all measured frequencies.
Subjective evaluation of sound processor performance. Measured by the Speech, Spatial and Quality (SSQ) scale from 0-10 where 0 represents "Not at all" and 10 represents "Perfect". Higher scores mean a better outcome.
Sentio 1 compared to previous sound processor. Average SSQ12 scores with Sentio 1 for each question, sub-scales and in total. Average SSQ12 scores with current sound processor for each question, sub-scales and in total. Difference in SSQ12 scores between Sentio 1 and current sound processor for each question, sub-scales and in total.
Subjective sound processor preference
Percentage (%) of subjects who prefer the Sentio 1 over current sound processor
To assess the degree to which Sentio 1 compensates for the BC hearing loss
Effective gain defined as the difference in dB between aided sound field thresholds with Sentio 1 and unmasked BC thresholds on the aided ear(s). The effective gain is calculated for all measured frequencies. Effective gain with Sentio 1, see definition above, calculated in average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).
To assess the difference between BC in-situ thresholds measured with Sentio 1 and conventional unmasked BC audiometry.
Difference in dB between Sentio 1 BC in situ thresholds and BC thresholds measured with conventional unmasked BC audiometry for the frequencies 500, 1000, 2000, 3000 and 4000 Hz
Assess safety with the Sentio 1 sound processor
Tabulation of AEs occurred throughout the investigation and percentage of individuals with reported AEs.

Full Information

First Posted
November 8, 2022
Last Updated
May 15, 2023
Sponsor
Oticon Medical
search

1. Study Identification

Unique Protocol Identification Number
NCT05628285
Brief Title
Evaluation of a Hearing Device for Transmitting Sound to the Inner Ear
Official Title
Evaluation of a Sound Processor for a Transcutaneous System
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 15, 2022 (Actual)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Oticon Medical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A single center study evaluating the performance of an externally worn sound processor for a transcutaneous bone anchored hearing system using audiological outcomes measures such as aided thresholds and self-evaluation questionnaires.
Detailed Description
Bone conduction hearing systems use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. Bone conduction devices currently on the market are divided into three types; transcutaneous direct drive, percutaneous (skin penetrating) direct drive and transcutaneous skin drive bone conduction devices. This evaluation focus on a sound processor used for a transcutaneous system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Conductive Hearing Loss, Mixed Hearing Loss

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sentio 1 sound processor
Arm Type
Experimental
Arm Description
The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
Intervention Type
Device
Intervention Name(s)
Sentio 1
Intervention Description
Sound processor
Primary Outcome Measure Information:
Title
To assess the improvement of hearing with the Sentio1 (PTA4)
Description
Functional gain with Sentio 1, i.e., the difference in dB between unaided and aided sound field thresholds, calculated on average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).
Time Frame
1 month
Secondary Outcome Measure Information:
Title
To assess the improvement of hearing with the Sentio1
Description
Functional gain with Sentio 1, i.e., the difference in dB between unaided and aided sound field thresholds, for all measured frequencies.
Time Frame
1 month
Title
Subjective evaluation of sound processor performance. Measured by the Speech, Spatial and Quality (SSQ) scale from 0-10 where 0 represents "Not at all" and 10 represents "Perfect". Higher scores mean a better outcome.
Description
Sentio 1 compared to previous sound processor. Average SSQ12 scores with Sentio 1 for each question, sub-scales and in total. Average SSQ12 scores with current sound processor for each question, sub-scales and in total. Difference in SSQ12 scores between Sentio 1 and current sound processor for each question, sub-scales and in total.
Time Frame
1 month
Title
Subjective sound processor preference
Description
Percentage (%) of subjects who prefer the Sentio 1 over current sound processor
Time Frame
1 month
Title
To assess the degree to which Sentio 1 compensates for the BC hearing loss
Description
Effective gain defined as the difference in dB between aided sound field thresholds with Sentio 1 and unmasked BC thresholds on the aided ear(s). The effective gain is calculated for all measured frequencies. Effective gain with Sentio 1, see definition above, calculated in average for frequencies 500, 1000, 2000 and 4000 Hz (PTA4).
Time Frame
1 month
Title
To assess the difference between BC in-situ thresholds measured with Sentio 1 and conventional unmasked BC audiometry.
Description
Difference in dB between Sentio 1 BC in situ thresholds and BC thresholds measured with conventional unmasked BC audiometry for the frequencies 500, 1000, 2000, 3000 and 4000 Hz
Time Frame
1 month
Title
Assess safety with the Sentio 1 sound processor
Description
Tabulation of AEs occurred throughout the investigation and percentage of individuals with reported AEs.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed Informed Consent Form Adult subjects (18 years or older) Subjects implanted with an I1 implant Fluent in Swedish Exclusion Criteria: Subjects who do not have the ability or are un-willing to follow investigational procedures/requirements, e.g., to complete questionnaires, according to investigator's discretion. Subject deemed unsuitable for any medical or other reason as judged by PI or medical responsible.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ann-Charlotte Persson
Organizational Affiliation
Habilitation & Health, Hearing organization Södra Gubberogatan 6, 416 63 Göteborg, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Habilitation & Health, Hearing organization
City
Gothenburg
ZIP/Postal Code
41663
Country
Sweden

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of a Hearing Device for Transmitting Sound to the Inner Ear

We'll reach out to this number within 24 hrs